Howard Cohen, RPh, MS, FASHP: Using Biosimilar Filgrastim

Howard Cohen, RPh, MS, FASHP, director of oncology pharmacy services for Yale New Haven Hospital, discusses using biosimilar filgrastim.


Does your center use biosimilars?

We are currently using biosimilars. We’ve actually created an approval process that we accept biosimilars as an acceptable product. We have brought in the first biosimilar; we use the product Zarxio in place of Neupogen. We did a full review of the product—a clinical review, the manufacturing process of it—and made a decision based on efficacy, safety and of cost-savings.